SCHEMBL25313503

SCHEMBL25313503

CC(C)(C)OC(=O)NCC(=O)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
TSHR P16473 1/20 0.59
KMT2A Q03164 1/20 0.59
SIGMAR1 Q99720 2/20 0.55
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
EPHX2 P34913 2/20 0.43
DTYMK P23919 1/20 0.42
EPHX1 P07099 1/20 0.42
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445038 0.87 ALDH1A1 (0.59) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL28018778 0.87 MEN1 (0.59) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL1329658 0.87 TSHR (0.62) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL4472678 0.85 TSHR (0.60) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL18883342 0.84 ALDH1A1 (0.47) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL524083 0.83 ALDH1A1 (0.56) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL30881207 0.83 ALDH1A1 (0.55) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL16466467 0.83 USP2 (0.44) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL20163037 0.83 TET2 (0.46) ALDH1A1MEN1TSHRKMT2ASIGMAR1
SCHEMBL31434503 0.83 ALDH1A1 (0.55) ALDH1A1MEN1TSHRKMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK 2023-12-28 US disclosed
EP-4217355-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 Forkhead Biotherapeutics, inc. (US) 2023-08-02 EP disclosed
WO-2022066938-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FORKHEAD BIOTHERAPEUTICS, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416228-A1 AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 FOXO1, FOXO3, GCKR ALDH1A1 3526/4885MEN1 985/4885TSHR 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.